The published record on SS-31, also studied as elamipretide, splits sharply between a strong laboratory rationale and a thin clinical one. A synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, it drew wide preclinical interest across cardiac, neuromuscular, renal, and eye conditions, yet most of its large human trials missed their primary endpoints. As of September 2025 it carries a single narrow FDA accelerated approval and remains investigational everywhere else.
SS-31 holds one narrow FDA accelerated approval for Barth syndrome granted in September 2025 and remains investigational with no proven clinical benefit for every other use.
Elamipretide is an aromatic-cationic tetrapeptide that crosses cell membranes and concentrates many times over in the inner mitochondrial membrane. Its central proposed action is not free-radical scavenging but selective binding to cardiolipin, the phospholipid that scaffolds the respiratory chain and helps shape cristae. This membrane-level target is what separated it from ordinary antioxidants, though it sits at the mechanism level of evidence rather than demonstrated clinical benefit.
SS-31's proposed mechanism centers on binding cardiolipin in the inner mitochondrial membrane to stabilize cristae and support ATP production, a pathway that remains its strongest evidence at the preclinical level.
The primary mitochondrial myopathy program centered on the MMPOWER series, where an early short-duration signal did not survive rigorous testing. MMPOWER-2's exploratory six-minute walk movement justified advancing to a larger study, but MMPOWER-3, the 24-week pivotal phase 3 trial, missed both co-primary endpoints. That confirmatory failure is the single most important fact about the drug's effectiveness in this indication.
| Feature | MMPOWER-2 | MMPOWER-3 |
|---|---|---|
| Design | Short crossover | 24-week pivotal phase 3 |
| Key reading | Exploratory six-minute walk movement | Co-primary six-minute walk and fatigue score |
| Result | Early signal, hypothesis-generating | Missed both co-primary endpoints |
| Weight | Not confirmatory | Prespecified confirmatory test |
MMPOWER-3, the pivotal 24-week phase 3 trial, missed both co-primary endpoints, with subcutaneous elamipretide failing to separate from placebo on six-minute walk distance and total fatigue score.
Cardiac testing rested on preclinical data suggesting SS-31 could limit reperfusion injury when blood flow returns to previously ischemic tissue. Both the flagship infarction trial and the heart failure studies failed to move their primary measures, and no cardiac indication advanced.
The EMBRACE STEMI trial found no significant infarct-size reduction versus placebo, and heart failure studies similarly missed their primary endpoints, so no cardiac indication advanced.
Across the program, isolated secondary and exploratory readings have appeared that stop short of confirming efficacy. Spread across many endpoints and small samples, these are the kind of scattered positives that multiple-comparison statistics predict will surface by chance.
Scattered secondary signals across small samples and many endpoints carry far less evidentiary weight than a prespecified primary endpoint a trial actually met, and they cannot establish that the drug works.
In rodent and other animal models, SS-31 repeatedly improved outcomes across ischemia-reperfusion, heart failure, kidney injury, and aging, which is why expectations ran high. Several forces routinely erode that promise once a mitochondrial drug reaches chronically ill, genetically mixed patients who may never reach the tissue exposure an animal study guarantees.
| Factor | Animal models | Human patients |
|---|---|---|
| Disease state | Acute, induced | Chronic, established |
| Genetics | Uniform strains | Heterogeneous by mutation |
| Target exposure | Dosed to guarantee engagement | Uncertain at tolerated doses |
| Endpoint signal | Single controlled measure | Hard to move across a mixed population |
A compelling membrane-level mechanism and strong animal data are a starting point for investigation, not a prediction of clinical success, and confirming human target engagement at tolerated doses has remained difficult for SS-31.
Several structural features of the SS-31 evidence base call for restraint when weighing any favorable reading. Small samples, effort-dependent measures, and the absence of a validated mitochondrial biomarker all make early positives fragile.
A missed prespecified primary endpoint is stronger evidence than any number of positive secondary or exploratory endpoints, because secondaries multiply the chance of a spurious hit while the primary is the single test the trial was powered to pass.
Development interest has narrowed toward the indications with the tightest mechanistic case and least discouraging early signals, away from the cardiac and general myopathy settings where large trials failed. Barth syndrome and ophthalmology, particularly geographic atrophy and dry AMD, remain the active areas. A trial that could genuinely change the picture would need to clear a specific bar.
With accelerated approval now secured for Barth syndrome, SS-31's status in ophthalmology and other settings is best described as narrowed and investigational, with effectiveness still unproven for those uses pending a confirmatory trial that meets a prespecified primary endpoint.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
